The nature of small-airway obstruction in chronic obstructive pulmonary disease.

By J. Hogg, F. Chu, Soraya Utokaparch, R. Woods, W. Elliott, L. Buzatu, R. Cherniack, R. Rogers, F. Sciurba, H. Coxson and 1 more. New England Journal of Medicine, 2004

3,833 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/73c40ef857fe24fbb2895e8b671462fe43a82196

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. J. Wedzicha
2. T. Seemungal
3. D. Parums
4. P. Barnes
5. P. Calverley
6. W. Macnee
7. G. Anderson

In Pulmonary and Respiratory Medicine

1. D. Parums
2. P. Barnes
3. J. Wedzicha
4. P. Calverley
5. T. Seemungal
6. A. Anzueto
7. Bartolome Celli
8. Jorgen Vestbo

Citations in the corpus

• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. (2007, background): “Parenchymal destruction due to emphysema also contributes to airflow limitation due to reduced elastic recoil (37).”
• How corticosteroids control inflammation: Quintiles Prize Lecture 2005 (2006, background): “Furthermore, histological analysis of peripheral airways of patients with severe COPD shows an intense inflammatory response, despite treatment with high doses of inhaled corticosteroids (Hogg et al., 2004).”
• Mediators of Chronic Obstructive Pulmonary Disease (2004, background): “The obstruction of peripheral airways due to inflammatory cell infiltration and fibrosis, together with inflammatory exudates in the lumen, correlate best with the severity of airflow obstruction, indicating the importance of chronic inflammation in COPD (Hogg et al., 2004).”
• Clearing the Air: A Review of the Effects of Particulate Matter Air Pollution on Human Health (2011, background): “Long-term exposure to PM results in airway remodeling and chronic inflammation [43].”
• The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. (2008, background): “COPD is a condition partly defined by an abnormal inflammatory response to noxious fumes (28).”
• Pathogenesis of chronic obstructive pulmonary disease. (2005, background): “Studies suggest an increase in B lymphocytes and in bronchial-associated lymphoid tissue in small airways as the disease progresses (10).”
• Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity (2004, background): “In addition, the formation of iBALT in chronic lung diseases, such as tuberculosis or COPD, may be a component of the patholog”
• Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. (2008, background): “While the pathogenesis of COPD is complex, studies suggest that airway inflammation plays an important role in disease progression (3, 5, 6). The intensity of inflammation relates to the degree of airflow obstruction ( 5 ), and may result from oxidantinduced damage.”
• Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution (2023, neutral): “Эти клетки, а также нейтрофилы и макро фаги выделяют воспалительные медиаторы и взаимо действуют со структурными клетками дыхательных пу тей, паренхимы и сосудов легких [90].”